We are live on ! Find out more
TBPH icon

Theravance Biopharma
TBPH

81 hedge funds and large institutions have $525M invested in Theravance Biopharma in 2016 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 23

24% more capital invested

Capital invested by funds: $425M → $525M (+$100M)

21% more call options, than puts

Call options by funds: $1.11M | Put options by funds: $920K

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

8% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 12

2% less funds holding

Funds holding: 83 → 81 (-2)

Holders
81
Holders Change
-2
Holders Change %
-2.41%
% of All Funds
2.16%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
11
Increased
31
Reduced
23
Closed
12
Calls
$1.11M
Puts
$920K
Net Calls
+$191K
Net Calls Change
+$97K

Top Buyers

Rank Fund Capital Flow
1
WIM
Woodford Investment Management
United Kingdom
+$28.8M
2
AC
Armistice Capital
New York
+$6.54M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$2.56M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$2M
5
Boston Partners
Boston Partners
Massachusetts
+$1.51M

Top Sellers

Rank Fund Capital Flow
1
SAM
Scion Asset Management
California
-$2.64M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$2M
3
PI
Putnam Investments
Massachusetts
-$1.23M
4
Norges Bank
Norges Bank
Norway
-$1.13M
5
Millennium Management
Millennium Management
New York
-$1.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
76
Geode Capital Management
Massachusetts
$3.63K +$251K +15,340 +9%
JP Morgan Chase
77
JP Morgan Chase
New York
$2K -$2.47K -151 -58%
PI
78
Putnam Investments
Massachusetts
– -$1.23M -74,725 Closed
GAM
79
Gotham Asset Management
New York
– -$733K -69,582 Closed
Millennium Management
80
Millennium Management
New York
– -$1.03M -62,978 Closed
Macquarie Group
81
Macquarie Group
Australia
– -$820K -50,000 Closed
HCM
82
Highbridge Capital Management
New York
– -$295K -17,976 Closed
Citadel Advisors
83
Citadel Advisors
Florida
– -$222K -13,537 Closed
Renaissance Technologies
84
Renaissance Technologies
New York
– -$178K -10,880 Closed
BNP Paribas Financial Markets
85
BNP Paribas Financial Markets
France
– -$102K -6,202 Closed
TRCT
86
Tower Research Capital (TRC)
New York
– -$2K -124 Closed
IA
87
IFP Advisors
Florida
– -$1K -57 Closed
US Bancorp
88
US Bancorp
Minnesota
– -$1K -41 Closed
CCA
89
Checchi Capital Advisers
California
– +$33 +2 New
Simplex Trading
90
Simplex Trading
Illinois
– +$49 +3 New
1 2 3
4

TBPH Hedge Fund Activity: Q1 2016 in Review

81 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q1 2016, worth a combined $525M — up 24% from $425M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of TBPH and 11 opened new positions — a net loss of 1 holder — while 23 trimmed existing stakes and 31 added.

The largest buyer was Woodford Investment Management, adding an estimated $28.8M. The largest seller was Scion Asset Management, cutting an estimated $2.64M.

  • 81 institutional investors held Theravance Biopharma (TBPH) as of Q1 2016, down from 83 in Q4 2015.
  • Funds reported $525M of Theravance Biopharma stock for Q1 2016, up 24% quarter-over-quarter.
  • 11 funds opened new Theravance Biopharma positions in Q1 2016 and 12 closed out, a net change of -1 holder.
  • The largest Theravance Biopharma buyer in Q1 2016 was Woodford Investment Management, an estimated $28.8M added.
  • The largest Theravance Biopharma seller in Q1 2016 was Scion Asset Management, an estimated $2.64M sold.

Based on aggregated 13F filings for Q1 2016.